Use of anti-Mullerian hormone for understanding ovulatory dysfunction in polycystic ovarian syndrome

Mathyk B. A., Cetin E., YILDIZ O. B.

CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, cilt.29, sa.6, ss.528-534, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 29 Sayı: 6
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1097/med.0000000000000772
  • Dergi Adı: CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.528-534
  • Anahtar Kelimeler: anovulation, anti-Mullerian hormone, polycystic ovary syndrome, FOLLICLE-STIMULATING-HORMONE, BODY-MASS INDEX, ANTIMULLERIAN HORMONE, AMH LEVELS, SERUM AMH, WOMEN, PCOS, SENSITIVITY, ESTRADIOL, AGE
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Purpose of review The aim of this review is to understand how anti-Mullerian hormone (AMH) contributes to ovulatory dysfunction in polycystic ovarian syndrome (PCOS). Recent findings In the last few years, new findings have emerged on AMH and its role on the central nervous system causing ovulatory dysfunction. Anovulation is a prominent feature of PCOS. Women with anovulatory PCOS have higher AMH levels than in ovulatory PCOS. Higher levels of AMH may contribute to the pathophysiology of PCOS through central and peripheral actions. Once universal standardization is achieved to measure serum AMH, the benefits would be significant in diagnosing women with PCOS.